--- title: Insulet (PODD) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/podd ticker: PODD as_of: 2026-10-17 sector: Healthcare industry: Medical - Devices --- # Insulet (PODD) Insulet (PODD) closed at $141.10 on Oct 16, 2026, overvalued by 15% vs its model value of $122.68 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $141.10 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $122.68 | | Price vs model | overvalued by 15% vs model | | Range of that model | $76.20 – $303.71 | | Market value | $9.8B | | P/E (fiscal 2025) | 40.5 | | Net margin (fiscal 2025) | 9.1% | | Free cash flow (fiscal 2025) | $377.7M | | Dividend yield (trailing twelve months) | 0.00% | | Beta | 1.10 | | Cost of capital (WACC) | 9.07% | | Business classification | High Growth (High revenue growth (~26% recent), Moderate margins (9% net margin), Highly cyclical earnings) | ## On the stock lists | List | Place | Figure | Page | | --- | ---: | ---: | --- | | Worst performing this year | #10 | −50.4% | https://sweetvaluelab.com/lists/worst-performing-this-year | | Insider buying | #37 | $162,217 | https://sweetvaluelab.com/lists/insider-buying | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $122.68 | $76.20 | $303.71 | | DCF · Perpetuity growth · 10y | cross check | $151.37 | $94.88 | $369.59 | | DCF · EBITDA exit · 5y | cross check | $125.30 | $75.52 | $184.18 | | DCF · EBITDA exit · 10y | cross check | $153.81 | $95.10 | $233.21 | | P/E · peers | cross check | $176.50 | $176.50 | $176.50 | | P/E · own history | cross check | $395.99 | $277.21 | $6,309.95 | | PEG | sanity check | $162.58 | $162.58 | $162.58 | | EV/EBITDA · peers | cross check | $244.13 | $244.13 | $244.13 | | EV/Revenue · peers | cross check | $283.51 | $273.90 | $382.87 | | Earnings power value | cross check | $12.19 | $10.00 | $15.25 | ## Insider activity (SEC Form 4) Past 90 days: 1 open-market buy ($162,217) and 0 open-market sales ($0); 10b5-1 plan sales included. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Oct 1, 2026 | Pease Flavia | EVP & CFO | Tax withholding | 1,882 | $246,146.8 | | Sep 30, 2026 | MAZELSKY JONATHAN JAY | Director | Grant / award | 141 | $18,396.3 | | Sep 30, 2026 | Huffines Robert Luther | Director | Grant / award | 178 | $23,223.7 | | Aug 21, 2026 | McEvoy Ashley | President and CEO | Open-market buy | 1,100 | $162,217 | | Aug 1, 2026 | Davis Lisa Blair | SVP, Chief HR Officer | Tax withholding | 244 | $40,345.4 | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Sep 21, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1145197/000119312526396779/d71204d8k.htm | | Sep 16, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1145197/000114519726000177/podd-20260914.htm | | Sep 10, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers | https://www.sec.gov/Archives/edgar/data/1145197/000114519726000175/podd-20260903.htm | | Aug 5, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1145197/000114519726000169/podd-20260630.htm | | Aug 5, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1145197/000114519726000167/podd-20260805.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Bridgewater | 2026-06-30 | 156,413 | $23.8M | 1 tracked managers in all. ## About Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the… --- Source: https://sweetvaluelab.com/stocks/podd (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.